Assembly Biosciences Set to Engage at Investor Conferences
Assembly Biosciences, Inc. (NASDAQ: ASMB), renowned for its innovative biotechnology solutions, has exciting plans to join discussions at two significant investor conferences soon. This engagement demonstrates their dedication to advancing therapeutics targeting serious viral diseases.
Participation in Major Conferences
Assembly Biosciences will participate in notable fireside chats that provide insights into their ongoing projects and future directions. These conferences are great platforms for the company to engage with investors and share their achievements in therapeutic developments.
H.C. Wainwright Liver Disease Virtual Conference
Dr. Anuj Gaggar, who serves as the Chief Medical Officer, will present a pre-recorded fireside chat during the H.C. Wainwright Liver Disease Virtual Conference. This presentation will be accessible on-demand starting in the early hours of October 21, 2025. It promises to offer valuable insights into the company's advancements in addressing liver diseases through their innovative therapies.
Guggenheim 2nd Annual Healthcare Innovation Conference
At the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for November 12, 2025, at 11 a.m. Eastern Time, Jason Okazaki, the CEO and President, along with Dr. Gaggar, will engage in a fireside chat. Their discussion will likely highlight the promising potential of their drug candidates and the ongoing strategies that aim to enhance patient outcomes.
The Mission of Assembly Biosciences
Assembly Biosciences is on a mission to create groundbreaking small-molecule therapeutics designed to significantly improve the treatment of serious viral infections like herpesvirus, hepatitis B (HBV), and hepatitis delta virus (HDV). With a team of industry veterans in virologic drug development, the company is committed to transforming the lives of patients affected by these conditions.
Insights into Innovative Therapeutics
Through committed research and development, Assembly is at the forefront of creating therapies that address the long-term challenges faced by patients with chronic viral infections. The upcoming conferences will spotlight how these innovations can potentially reshape the therapeutic landscape.
Contacting Assembly Biosciences
Investor Relations
For additional details or inquiries regarding their investor activities, you can reach out to Shannon Ryan, Senior Vice President of Investor Relations, Corporate Affairs, and Alliance Management at (415) 738-2992 or via email at investor_relations@assemblybio.com.
Media Contacts
For media-related questions, the team at Sam Brown LLC can be contacted. Alyssa Kuciunas is reachable at (331) 481-3751, or by email at ASMBMedia@sambrown.com.
Frequently Asked Questions
What major conferences will Assembly Biosciences attend?
They will participate in the H.C. Wainwright Liver Disease Virtual Conference and the Guggenheim 2nd Annual Healthcare Innovation Conference.
Who is the CEO of Assembly Biosciences?
Jason Okazaki serves as the CEO and President.
What is the focus of Assembly Biosciences?
The company develops innovative therapeutics targeting viral diseases, focusing particularly on herpesvirus and hepatitis infections.
How can I register for the webcasts?
Registrations can be made through the Events and Presentations section of Assembly Biosciences' website.
What are Assembly's future plans for therapeutics?
The company continues to focus on advancing therapeutic development for serious viral diseases, aiming to enhance patient outcomes significantly.
